Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IScience_07-19-2021-ISTR-iScience-62686

ABSTRACT: We have mapped the epitopes of NbHSA for albumin binding using cross-linking mass spectrometry. We also employed PRM quantitative proteomics for accurate, multiplex Nb pharmacokinetic analysis.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Mus Musculus (ncbitaxon:10090)

SUBMITTER: Yi Shi

PROVIDER: MSV000086104 | MassIVE |

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

abe4747_articlecontent_v2_Xiangetal_CXMS

Project description:Cross-linking coupled to LC-MS analysis of RBD-Nb complexes using the DSS cross-linker

| MSV000086198 | MassIVE

Immuno-Detection by sequencing (ID-seq) enables large-scale high- dimensional phenotyping in cells

Project description:We developed a sequencing-based immunodetection method which makes it possible to multiplex measurements of many different epitopes from proteins and phosphoproteins in a high throughput setting. With these DNA-tagged antibodies and dedicated sample preparation protocol, we studied the effect of hundreds of kinase inhibitors on 70 (phospho-)proteins in primary human skin cells.

2017-07-01 | GSE100135 | GEO

Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma

Project description:Neuroblastoma (NB) is the most common extracranial malignant tumor in children. Although the survival rate of NB has improved over the years, the outcome of NB still remains poor for over 30% of cases. A more accurate risk stratification remains a key point in the study of NB and the availability of novel prognostic biomarkers of 'high-risk' at diagnosis could help improving patient stratification and predicting outcome. In this paper we show a biomarker discovery approach applied to the plasma of 172 NB patients. Plasma samples from a first cohort of NB patients and age-matched healthy controls were used for untargeted metabolomics analysis based on high-resolution mass spectrometry (HRMS). Differential expression analysis highlighted a number of metabolites annotated with a high degree of identification. Among them, 3-O-methyldopa (3-O-MD) was validated in a second cohort of NB patients using a targeted metabolite profiling approach and its prognostic potential was also analyzed by survival analysis on patients with 3 years follow-up. High expression of 3-O-MD was associated with worse prognosis in the subset of patients with stage M tumor (log-rank p < 0.05) and, among them, it was confirmed as a prognostic factor able to stratify high-risk patients older than 18 months. 3-O-MD might be thus considered as a novel prognostic biomarker of NB eligible to be included at diagnosis among catecholamine metabolite panels in prospective clinical studies. Further studies are warranted to exploit other potential biomarkers highlighted using our approach.

2023-07-14 | MTBLS4294 | MetaboLights

Novel TCR sequencing and cloning methods for sensitive and quantitative interrogation of repertoires and rapid isolation of tumor-reactive TCRs

Project description:We report on SEQTR, a novel high-throughput approach to analyze human and mouse repertoires that is more sensitive, reproducible and accurate as compared to commonly-used multiplex PCR and 5'RACE assays.

2023-05-22 | GSE225984 | GEO

Reactivity of commercial antibodies targeting human histone H2B N-terminal tail on the Intel array platform

Project description:The aim of the study was to test the Intel array platform and map the H2B epitopes bound by commercial antibody reagents. We also tested the ability of SET7 PKMT to methylate Intel array peptides. We diluted antibody reagents 1:1000 and incubated dilutions on the silicon-based Intel array platorm. We mapped antibody binding epitopes and SET7 PKMT methylation target peptides using a novel, silicon-based array platform with 8820 individual peptide features comprising every possible contiguous peptide from 1-21 a.a. in length within the 21-mer N-terminal tail of human histone H2B.

2011-12-02 | E-GEOD-34034 | biostudies-arrayexpress

Project description:Albumin

| PRJEB48450 | ENA

PRM-based quantitative proteomic analysis of mouse tissues, testicular cells and cell lines

Project description:PRM analysis of RPL39L, RPL10L and RPL3L in 9 mouse tissues, including testis, fat, brain, liver, kidney, lung, skeletal muscle, heart and spleen; PRM analysis of RPL39 and RPL39L, RPL10 and RPL10L, and RPL22 and RPL22L1 in testicular cells; PRM analysis of RPL39L and RPL39 in RibosomeRPL39L-/- and wild type mouse spermatocytes and spermatids; PRM analysis of 17 down-regulated proteins and 1 unchanged protein (DYNC1LI2) in RibosomeRPL39L-/- testes; PRM analysis of RPL39 and RPL39L in GC-1 ribosomes, and RibosomeRPL39L-/- and wild type N2a ribosomes, Consistency between the observed and expected signal ratios of the light and heavy peptides by PRM in serial dilution experiments. Bovine serum albumin (BSA) as a negative control.

2022-09-30 | PXD020922 | Pride

PRM-based quantitative proteomic analysis of ribosomes in GC-1 cell line

Project description:Relative protein quantification of RPL4 and RPL39L in non-ribosome, 40S, 60S and ribosome fractions by PRM;Absolute quantification of RPL39 and RPL39L levels in ribosomes of GC-1 wild type cell, and RPL39L-IRES-eGFP-overexpressed RibosomeCore-/Y GC-1 cells with or without dox-induced expression of RPL39 by PRM. Bovine serum albumin (BSA) as a negative control.

2022-10-19 | PXD037257 | Pride

In vitro expression in FGFR inhibitor sensitive and resistant cell lines

Project description:The challenge of developing effective pharmacodynamic biomarkers for pre-clinical and clinical testing of FGFR signalling inhibition is significant. Assays that rely on the measurement of phospho-protein epitopes can be limited by the availability of effective antibody detection reagents. Transcript profiling enables accurate quantification of many biomarkers and a broader representation of pathway modulation. To identify dynamic transcript biomarkers of FGFR signalling inhibition by AZD4547, a potent inhibitor of FGF receptor 1, 2 and 3, a gene expression profiling study was performed in FGFR2 amplified drug sensitive tumour cell lines.

2016-08-25 | E-MTAB-4749 | biostudies-arrayexpress

Simple oligonucleotide-based multiplexing of single-cell chromatin accessibility

Project description:we reported the development of an accurate, easy-to-use and scalable system (SNuBar) for multiplexing single cell ATAC or multi-omics (ATAC&RNA) assays, and applied this method to multiplex therapy combinations in a lung cancer mouse model and macro-spatial regions of normal breast tissues and samples.

2021-10-20 | GSE162798 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data